Corentec Co

Corentec Co EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Corentec Co (104540.KQ) as of Nov 6, 2026 is 8.57. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 11.52 — a change of -25.65% (lower).

EV/EBITDA

8.57

YoY

-25.65%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Corentec Co is 2025 8.57 . EV/EBITDA (Enterprise Value to EBITDA) of Corentec Co was 2024 11.52 . It decreases by -25.65% lower compared to the previous year.

The Corentec Co EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
-3.74 KRW
Jan 1, 2019
18.49 KRW
Jan 1, 2020
16.82 KRW
Jan 1, 2021
14.74 KRW
Jan 1, 2022
6.58 KRW
Jan 1, 2023
4.96 KRW
Jan 1, 2024
11.52 KRW
Jan 1, 2025
8.57 KRW
The Corentec Co EV/EBITDA history
YEAREV/EBITDAYoY
8.57-25.65%
11.52+132.31%
4.96-24.66%
6.58-55.32%
14.74-12.36%
16.82-9.04%
18.49-594.42%
-3.74-81.64%
-20.37-193.54%
21.78-15.99%
25.92-54.99%
57.58—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Corentec Co Stock analysis

What does Corentec Co do? Corentec Co., Ltd. manufactures and sells artificial articulations, including hip, knee, and spine products. The company offers hip products under the BENCOX brand, featuring primary systems, hemi-arthroplasty systems, and revision systems such as cementless femoral stems and acetabular cups. Knee products are sold under the LOSPA brand, including fixed and mobile primary knee systems and revision systems. Spine products also carry the LOSPA IS brand, comprising pedicle screws and peek cages. Corentec distributes these products domestically and internationally, targeting healthcare providers and hospitals that require orthopedic solutions. The firm’s revenue comes from the sale of hip, knee, and spine products through its BENCOX, LOSPA, and LOSPA IS brand portfolios. Domestic and overseas markets are key segments, with the company focusing on orthopedic surgeons and medical institutions that purchase these specialized medical devices. Corentec’s product lines are designed for both primary and revision surgeries, catering to a broad range of orthopedic needs in the healthcare sector. Corentec Co., Ltd. serves healthcare providers globally, with its BENCOX brand dominating hip product sales and LOSPA/LOSPA IS covering knee and spine solutions. The company’s distribution strategy emphasizes direct sales to hospitals and medical centers, ensuring consistent product availability for surgical procedures. By maintaining distinct brand identities for each product category, Corentec efficiently targets specific medical specialties within the orthopedic market. Corentec Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Corentec Co stock

EV/EBITDA (Enterprise Value to EBITDA) of Corentec Co is 8.57 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Corentec Co changed from 11.52 to 8.57, representing a -25.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Corentec Co since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Corentec Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Corentec Co

All Key Metrics — Corentec Co